🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 23 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 06/12/2011 | 29,71 | 30,00 | 29,29 | 29,66 | +0,20% | 2,39% | 2.864.500 |
| 05/12/2011 | 29,45 | 29,75 | 28,57 | 29,60 | +1,20% | 4,01% | 3.996.500 |
| 02/12/2011 | 29,57 | 29,85 | 29,08 | 29,25 | -0,48% | 2,60% | 4.009.400 |
| 01/12/2011 | 28,68 | 29,47 | 28,55 | 29,39 | +1,38% | 3,21% | 3.539.200 |
| 30/11/2011 | 27,72 | 29,00 | 27,52 | 28,99 | +6,07% | 5,34% | 4.687.600 |
| 29/11/2011 | 27,32 | 27,57 | 26,75 | 27,33 | +0,33% | 3,00% | 4.599.600 |
| 28/11/2011 | 27,12 | 27,55 | 26,80 | 27,24 | +2,41% | 2,77% | 3.112.500 |
| 25/11/2011 | 26,80 | 27,23 | 26,50 | 26,60 | -1,26% | 2,72% | 836.400 |
| 23/11/2011 | 27,75 | 27,89 | 26,89 | 26,94 | -3,51% | 3,60% | 1.769.600 |
| 22/11/2011 | 27,57 | 28,31 | 27,34 | 27,92 | +1,31% | 3,52% | 2.845.100 |
| 21/11/2011 | 28,08 | 28,49 | 27,38 | 27,56 | -2,58% | 3,95% | 4.610.300 |
| 18/11/2011 | 28,94 | 29,01 | 27,84 | 28,29 | -2,48% | 4,04% | 4.240.000 |
| 17/11/2011 | 29,18 | 29,62 | 28,78 | 29,01 | -0,85% | 2,88% | 3.345.800 |
| 16/11/2011 | 29,61 | 30,00 | 29,18 | 29,26 | -1,48% | 2,77% | 3.239.100 |
| 15/11/2011 | 29,96 | 30,20 | 29,44 | 29,70 | -1,10% | 2,54% | 2.922.200 |
| 14/11/2011 | 31,01 | 31,10 | 29,57 | 30,03 | -4,33% | 4,93% | 4.370.500 |
| 11/11/2011 | 32,04 | 32,18 | 31,38 | 31,39 | -1,84% | 2,50% | 3.259.700 |
| 10/11/2011 | 31,52 | 32,66 | 31,21 | 31,98 | +3,63% | 4,60% | 6.052.900 |
| 09/11/2011 | 30,04 | 31,40 | 29,24 | 30,86 | +1,35% | 7,19% | 7.734.200 |
| 08/11/2011 | 32,68 | 32,68 | 30,18 | 30,45 | -8,34% | 7,65% | 11.503.700 |
| 07/11/2011 | 34,95 | 35,10 | 32,92 | 33,22 | -9,31% | 6,24% | 6.292.500 |
| 04/11/2011 | 36,29 | 37,05 | 34,95 | 36,63 | +0,00% | 5,79% | 3.375.700 |
| 03/11/2011 | 37,42 | 37,76 | 35,45 | 36,63 | -0,73% | 6,17% | 3.249.300 |
| 02/11/2011 | 38,11 | 38,42 | 36,43 | 36,90 | -2,33% | 5,22% | 4.218.100 |
| 01/11/2011 | 37,49 | 38,50 | 36,86 | 37,78 | -4,57% | 4,37% | 4.431.500 |
| 31/10/2011 | 40,30 | 40,62 | 39,47 | 39,59 | -4,79% | 2,85% | 3.586.200 |
| 28/10/2011 | 42,75 | 42,75 | 39,76 | 41,58 | -2,35% | 6,99% | 6.820.100 |
| 27/10/2011 | 44,00 | 44,25 | 41,44 | 42,58 | -0,72% | 6,39% | 4.003.600 |
| 26/10/2011 | 43,67 | 43,72 | 40,56 | 42,89 | -1,02% | 7,24% | 3.216.700 |
| 25/10/2011 | 43,81 | 44,00 | 42,86 | 43,33 | -1,55% | 2,60% | 2.403.700 |